The cardiovascular safety of rosiglitazone

  title={The cardiovascular safety of rosiglitazone},
  author={R. Ajjan and P. J. Grant},
  journal={Expert Opinion on Drug Safety},
  pages={367 - 376}
  • R. Ajjan, P. J. Grant
  • Published 2008
  • Medicine
  • Expert Opinion on Drug Safety
  • Background: Thiazolidinediones (rosiglitazone, pioglitazone) influence insulin sensitivity and are used for the treatment of Type 2 diabetes. Rosiglitazone achieves sustained improvements in glycaemic control, whilst having pleiotropic effects on cardiovascular risk factors. However, analysis of cardiovascular outcomes has been controversial. Objectives: Review the cardiovascular safety of rosiglitazone by conducting a literature search. Methods: We conducted a PubMed search and critically… CONTINUE READING
    21 Citations

    Topics from this paper.

    Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives
    • 45
    Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    • 68
    Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone.
    • 11
    Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial.
    • 5
    Insulin and Other Antidiabetic Agents
    • 3
    Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment.
    • 78
    • PDF


    The cardiovascular effects of the thiazolidinediones: a review of the clinical data.
    • 26
    Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    • 4,240
    • Highly Influential
    • PDF
    Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
    • 785
    Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol
    • 134
    • PDF
    Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
    • 762
    • PDF
    Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death
    • 214
    • PDF
    A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    • 286
    • PDF
    Thiazolidinediones and Blood Lipids in Type 2 Diabetes
    • 172
    • PDF
    Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers
    • 93
    • PDF